Publications by authors named "Zhizhao Guo"
Article Synopsis
- Researchers developed hpCas13d, an RNA nuclease, to effectively prevent hypertrophic cardiomyopathy in a specific mouse model, but further studies are needed for evaluating its long-term effects and safety.
- In a series of experiments, neonatal Myh6 mice were treated with AAV-hpCas13d, showing sustained absence of pathogenic Myh6 transcripts and improvements in heart function over 12 months without significant tissue damage or adverse immune reactions.
- These findings highlight the potential of AAV-hpCas13d as a viable gene therapy option for treating heart diseases, suggesting its readiness for further clinical application.
Background: Familial hypertrophic cardiomyopathy has severe clinical complications of heart failure, arrhythmia, and sudden cardiac death. Heterozygous single nucleotide variants (SNVs) of sarcomere genes such as are the leading cause of this type of disease. CRISPR-Cas13 (clustered regularly interspaced short palindromic repeats and their associated protein 13) is an emerging gene therapy approach for treating genetic disorders, but its therapeutic potential in genetic cardiomyopathy remains unexplored.
View Article and Find Full Text PDFNon-ferrous metal smelting emits large amounts of organic compounds into the atmosphere. Herein, 20 parent polycyclic aromatic hydrocarbons (PPAHs), 9 nitrated PAHs (NPAHs), 14 chlorinated PAHs (ClPAHs), and 6 alkylated PAHs (APAHs) in atmospheric samples from a typical non-ferrous metal smelting plant (NMSP) and residential areas were detected. In NMSP, benzo[a]pyrene, dibenz[a,h]anthracene, 6-nitrochrysene, 9-chlorofluorene, and 1-methylfluorene were the predominant compounds in the particulate phase, while phenanthrene constituted 57.
View Article and Find Full Text PDF